Targin for Non-cancer Pain
- Conditions
- Non Cancer Pain
- Interventions
- Drug: Oxycodone/naloxone prolonged release tablets
- Registration Number
- NCT01918098
- Lead Sponsor
- Mundipharma (China) Pharmaceutical Co. Ltd
- Brief Summary
To determine the improvement in symptoms of constipation in subjects receiving treatment with oxycodone/naloxone prolonged release tablets (OXN) compared to oxycodone prolonged release tablets (OXY) based on the Bowel Function Index (BFI)
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 230
Not provided
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Oxycodone prolonged release tablets Oxycodone/naloxone prolonged release tablets Dose strength:5mg,10mg, 20mg,PO,q12h.daily dose from 10mg to 50mg.treatment duration:12 weeks Oxycodone/naloxone prolonged release tablets Oxycodone/naloxone prolonged release tablets Dose strength:5/2.5 mg,10/5mg, 20/10mg,PO,q12h.daily dose from 10/5mg to 50/25mg.treatment duration:12 weeks
- Primary Outcome Measures
Name Time Method Bowel function index(BFI) 12 Weeks 12 weeks
- Secondary Outcome Measures
Name Time Method Modified BPI-SF-Average Pain over the last 24 hours 12 weeks
Trial Locations
- Locations (31)
Guangzhou First People's Hospital
🇨🇳Guangzhou, Guangdong, China
Second Affiliated Hospital of Shan Tou University Medical College
🇨🇳Shan Tou, Guangdong, China
Hebei General Hospital
🇨🇳Shijiazhuang, Hebei, China
Beijing friendship hospital
🇨🇳Beijing, China
Beijing Tiantan Hospital
🇨🇳Beijing, China
Beijing Union hospital
🇨🇳Beijing, China
Peking Union Medical College Hospital
🇨🇳Beijing, China
Peking University Third Hospital
🇨🇳Beijing, China
The first affiliated hospital of Bengbu medical collage
🇨🇳Bengbu, China
The third Xiangya hospital of central south university
🇨🇳Changsha, China
Scroll for more (21 remaining)Guangzhou First People's Hospital🇨🇳Guangzhou, Guangdong, China